Final ID: Mo3137
Mirza Imaduddin, Morsy Mohammed, Levitan Irena, Raj Usha, Mahmoud Abeer
37,500 man-years of clinical expertise validate the cardio-metabolic benefits of empagliflozin-linagliptin in type 2 diabetes: findings from the amplified consensusNair Tiny, Jabbar P, Ray Saumitra, Hazra Prakash, Gupta Sushil, Joshi Ameya, Shaikh Shehla, B Jayagopal, Pandit Kaushik, Sharma D, Seshadri Krishna, S Sridhar